Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s): N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Healthcare Psychedelics

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

NDAQ:MNMD - Post by User

Mind Medicine (MindMed) Inc

Bullboard Posts

Post by paulindoonon Aug 03, 2017 2:43pm

214 Views

Post# 26544291

Share price collapsed

OK so with no news fickle PIs will lose start to have 2nd thoughts. But this has dropped a lot.
Now I will acknowledge that there are perhaps lower hanging fruit out there (BTW check out NVO.V) but the potential here is quite high. So why the big drop fm the hi last March of $1.52!! Any insights?

52WK RANGE

0.24 - 1.70

Bullboard Posts

Full Circle Lithium goes global with its battery fire-fighter